Smith & Nephew Poised for Upside in Transition to Growth Delivery, RBC Says

MT Newswires Live10-20

Smith & Nephew's (SNN) risk-reward profile remains "skewed to the upside" as the company transitions from recovery mode to growth delivery, RBC Capital Markets said in a Monday note previewing the company's Capital Markets Day in December.

Upcoming guidance is expected to include a compound annual revenue growth rate of 5% to 6%, with Sport Medicine being a primary driver of mid-term growth, bolstered by steady progress in Wound Care and moderate growth in Orthopedics, RBC analysts said. They expect the company to provide earnings before interest and taxes margin expansion guidance of 2 to 3 percentage points, mainly driven by a recovery in Orthopedics, implying a low-single-digit upside to consensus at the midpoint.

With the company moving to stability after addressing operational challenges, its focus has now shifted to seizing longer-term opportunities, according to the note. The analysts said they are rolling forward their valuation on Smith & Nephew.

RBC reiterated the company' stock rating at outperform and raised the price target to 17 British pounds ($22.8) from 14 pounds.

Price: 36.39, Change: +0.05, Percent Change: +0.15

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2576686887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 22:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576686887","market":"sg","top_or_hot":-1,"title":"Smith & Nephew Poised for Upside in Transition to Growth Delivery, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Smith &amp; Nephew's (SNN) risk-reward profile remains \"skewed to the upside\" as the company transitions from recovery mode to growth delivery, RBC Capital Markets said in a Monday note previewing the company's Capital Markets Day in December.</p><p>Upcoming guidance is expected to include a compound annual revenue growth rate of 5% to 6%, with Sport Medicine being a primary driver of mid-term growth, bolstered by steady progress in Wound Care and moderate growth in Orthopedics, RBC analysts said. They expect the company to provide earnings before interest and taxes margin expansion guidance of 2 to 3 percentage points, mainly driven by a recovery in Orthopedics, implying a low-single-digit upside to consensus at the midpoint.</p><p>With the company moving to stability after addressing operational challenges, its focus has now shifted to seizing longer-term opportunities, according to the note. The analysts said they are rolling forward their valuation on Smith &amp; Nephew.</p><p>RBC reiterated the company' stock rating at outperform and raised the price target to 17 British pounds ($22.8) from 14 pounds.</p><p>Price: 36.39, Change: +0.05, Percent Change: +0.15</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Smith & Nephew Poised for Upside in Transition to Growth Delivery, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSmith & Nephew Poised for Upside in Transition to Growth Delivery, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-20 22:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Smith &amp; Nephew's (SNN) risk-reward profile remains \"skewed to the upside\" as the company transitions from recovery mode to growth delivery, RBC Capital Markets said in a Monday note previewing the company's Capital Markets Day in December.</p><p>Upcoming guidance is expected to include a compound annual revenue growth rate of 5% to 6%, with Sport Medicine being a primary driver of mid-term growth, bolstered by steady progress in Wound Care and moderate growth in Orthopedics, RBC analysts said. They expect the company to provide earnings before interest and taxes margin expansion guidance of 2 to 3 percentage points, mainly driven by a recovery in Orthopedics, implying a low-single-digit upside to consensus at the midpoint.</p><p>With the company moving to stability after addressing operational challenges, its focus has now shifted to seizing longer-term opportunities, according to the note. The analysts said they are rolling forward their valuation on Smith &amp; Nephew.</p><p>RBC reiterated the company' stock rating at outperform and raised the price target to 17 British pounds ($22.8) from 14 pounds.</p><p>Price: 36.39, Change: +0.05, Percent Change: +0.15</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNN","symbol_name":"Smith & Nephew PLC ADS","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2576686887","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576686887","pubTimestamp":1760969467,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Smith & Nephew's  risk-reward profile remains \"skewed to the upside\" as the company transitions from recovery mode to growth delivery, RBC Capital Markets said in a Monday note previewing the company's Capital Markets Day in December.Upcoming guidance is expected to include a compound annual revenue growth rate of 5% to 6%, with Sport Medicine being a primary driver of mid-term growth, bolstered by steady progress in Wound Care and moderate growth in Orthopedics, RBC analysts said. They expect the company to provide earnings before interest and taxes margin expansion guidance of 2 to 3 percentage points, mainly driven by a recovery in Orthopedics, implying a low-single-digit upside to consensus at the midpoint.With the company moving to stability after addressing operational challenges, its focus has now shifted to seizing longer-term opportunities, according to the note. The analysts said they are rolling forward their valuation on Smith & Nephew.RBC reiterated the company' stock rati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNN":"Smith & Nephew PLC ADS","BK4082":"医疗保健设备"},"translate_title":"加拿大皇家银行表示，施乐辉有望在向增长交付转型的过程中实现上行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNN":1},"content_text":"Smith & Nephew's (SNN) risk-reward profile remains \"skewed to the upside\" as the company transitions from recovery mode to growth delivery, RBC Capital Markets said in a Monday note previewing the company's Capital Markets Day in December.Upcoming guidance is expected to include a compound annual revenue growth rate of 5% to 6%, with Sport Medicine being a primary driver of mid-term growth, bolstered by steady progress in Wound Care and moderate growth in Orthopedics, RBC analysts said. They expect the company to provide earnings before interest and taxes margin expansion guidance of 2 to 3 percentage points, mainly driven by a recovery in Orthopedics, implying a low-single-digit upside to consensus at the midpoint.With the company moving to stability after addressing operational challenges, its focus has now shifted to seizing longer-term opportunities, according to the note. The analysts said they are rolling forward their valuation on Smith & Nephew.RBC reiterated the company' stock rating at outperform and raised the price target to 17 British pounds ($22.8) from 14 pounds.Price: 36.39, Change: +0.05, Percent Change: +0.15","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576686887","isCrawlerRequest":true}